Novartis confident Entresto sales will reach around $5 bn
ZURICH: Novartis remains confident that sales for its new heart failure medicine Entresto will peak at around $5 billion, the Swiss drugmaker said in a presentation for an investor event on Wednesday.
Introduced last year, Entresto got off to a sluggish start, with only $17 million first-quarter sales. Novartis on Monday stuck to its full-year forecast of $200 million in revenue from Entresto "as of right now".
Novartis also said on Wednesday its Cosentyx product had the potential to deliver around $4 billion to $5 billion in sales across the dermatology and rheumatology indications.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd